A Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Naïve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)

Stopped This was a strategic decision for business planning purposes and not out of concern for patient safety.

Conditions

• Locally Advanced Squamous Non-Small Cell Lung Cancer
• Metastatic Squamous Non-Small Cell Lung Cancer

Interventions

• DRUG: Necitumumab
• DRUG: Gemcitabine
• DRUG: Carboplatin

Sponsor

Eli Lilly and Company